<DOC>
	<DOCNO>NCT00615758</DOCNO>
	<brief_summary>To evaluate efficacy toxicity erlotinib first line treatment patient locally advanced/metastatic ( stage IIIB/IV ) NSCLC , clinical predictor response tyrosine kinase inhibitor ( erlotinib , gefitinib ) , female gender , never-smoking status adenocarcinoma histology . Furthermore , erlotinib-sensitivity correlate presence EGFR mutation exon 18 , 19 21 , population</brief_summary>
	<brief_title>Erlotinib 1st Line Treatment NSCLC Stage IIIB/IV</brief_title>
	<detailed_description>A randomized , placebo-controlled phase III trial erlotinib versus placebo , 700 patient demonstrated therapy tyrosine kinase inhibitor ( TKI ) prolongs survival first second line therapy patient advance NSCLC . Statistically significant clinically relevant difference observe overall progression free survival favour erlotinib . Moreover , several clinical factor correlate response gefitinib erlotinib , include never smoking status , female gender , Asian ethnicity adenocarcinoma histology ( especially bronchioalveolar carcinoma ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm , unresectable locally advanced ( stage IIIB pleural effusion ) and/or metastatic ( stage IV ) NSCLC No previous therapy advanced/metastatic NSCLC allow age &gt; 18 year bidimensionally measurable disease nonsmoker ( exsmokers less 5 packyears smoke history ) adenocarcinoma histology performance status ( WHO ) 03 adequate liver ( serum bilirubin &lt; 1.5 time upper normal limit ( UNL ) ; AST ALT &lt; 2.5 time UNL absence demonstrable liver metastasis , &lt; 5 time UNL presence liver metastasis ) ; adequate renal function ( serum creatinine &lt; 1.5 time UNL ) ; bone marrow ( neutrophils ≥ 1.5x 109 /L , platelet ≥ 100x 109 /L ) function previous radiotherapy , either adjuvant setting treatment metastatic disease allow provide measurable lesion outside radiation field patient able take oral medication tissue sample tumour mutational analysis require serious chronic skin condition ( e.g . psoriasis , eczema ) would preclude study participation active infection history significant cardiac disease ( unstable angina , congestive heart failure , myocardial infarction within previous 6 month , ventricular arrhythmia ) malnutrition ( loss ≥ 20 % original body weight ) performance status : 4 psychiatric illness social situation would preclude study compliance pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Erlotinib</keyword>
	<keyword>Biological therapy</keyword>
	<keyword>Tyrosin Kinase Inhibitor therapy</keyword>
</DOC>